Trial Profile
Effects of anti von Willebrand factor nanobody on endothelial function in patients with stable angina pectoris and single-vessel coronary artery disease
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2011
Price :
$35
*
At a glance
- Drugs Caplacizumab (Primary)
- Indications Angina pectoris; Coronary artery disease; Embolism and thrombosis
- Focus Pharmacodynamics
- 07 Mar 2011 New trial record